BIT.AX - Biotron Limited

ASX - ASX Delayed price. Currency in AUD

Biotron Limited

56 Delhi Road
Suite 19
North Ryde, NSW 2113
Australia
61 2 9805 0488
http://www.biotron.com.au

SectorHealthcare
IndustryBiotechnology
Full-time employees5

Key executives

NameTitlePayExercisedAge
Dr. Michelle Miller BSc, MSc, Ph.D., GCertAppFin (Finsia)CEO, MD & Exec. DirectorN/AN/AN/A
Mr. Peter James Nightingale B.Econ, CACompany Sec.N/AN/A60
Dr. John Wilkinson Ph.D.Chief Scientific OfficerN/AN/AN/A
Amounts are as of 31December,2017, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as dengue, zika, and influenza virus. Biotron Limited is based in North Ryde, Australia.

Corporate governance

Biotron Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.